Reply to the letter from Janssen et al

por Vlasveld, L.T., Rankin, E.M., Melief, C.J.M.
Publicado 1994

Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

por Vermeij, R., Leffers, N., van der Burg, S. H., Melief, C. J., Daemen, T., Nijman, H. W.
Publicado 2011

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.

por Vlasveld, L. T., Rankin, E. M., Hekman, A., Rodenhuis, S., Beijnen, J. H., Hilton, A. M., Dubbelman, A. C., Vyth-Dreese, F. A., Melief, C. J.
Publicado 1992

Antibodies against p53 are associated with poor prognosis of colorectal cancer.

por Houbiers, J. G., van der Burg, S. H., van de Watering, L. M., Tollenaar, R. A., Brand, A., van de Velde, C. J., Melief, C. J.
Publicado 1995

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.

por Vlasveld, L. T., Hekman, A., Vyth-Dreese, F. A., Rankin, E. M., Scharenberg, J. G., Voordouw, A. C., Sein, J. J., Dellemijn, T. A., Rodenhuis, S., Melief, C. J.
Publicado 1993

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond

por Britten, C. M., Janetzki, S., van der Burg, S. H., Huber, C., Kalos, M., Levitsky, H. I., Maecker, H. T., Melief, C. J. M., O’Donnell-Tormey, J., Odunsi, K., Old, L. J., Pawelec, G., Roep, B. O., Romero, P., Hoos, A., Davis, M. M.
Publicado 2010

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients

por van Meir, H., Nout, R. A., Welters, M. J. P., Loof, N. M., de Kam, M. L., van Ham, J. J., Samuels, S., Kenter, G. G., Cohen, A. F., Melief, C. J. M., Burggraaf, J., van Poelgeest, M. I. E., van der Burg, S. H.
Publicado 2016